This study is looking at type 2 diabetes, a condition where the body does not properly control blood sugar levels. The study will test a combination medication called cagrilintide semaglutide, which contains two active substances that work together to help lower blood sugar and reduce body weight. This medication will be compared to another diabetes medicine called tirzepatide, which is available under the brand name Mounjaro. Both medications are given as injections under the skin once a week. The study will include people with type 2 diabetes who are already taking metformin, an SGLT2 inhibitor, or both of these medications, but whose blood sugar levels are not well controlled with these treatments alone.
The purpose of the study is to find out if cagrilintide semaglutide is at least as good as tirzepatide at lowering blood sugar levels, and whether it might be better at helping people lose weight. The study will also look at other health measures such as blood pressure, waist size, cholesterol levels, and overall quality of life. Additionally, the study will check how safe these medications are and what side effects people may experience while taking them.
People taking part in this study will receive either cagrilintide semaglutide or tirzepatide for 60 weeks. During this time, they will continue taking their current diabetes medications. Throughout the study, participants will have regular visits where their blood sugar levels, body weight, blood pressure, and other health measurements will be checked. Blood tests will be done to measure a substance called HbA1c, which shows average blood sugar levels over the past few months, as well as cholesterol and other blood fats. Participants will also be asked to complete questionnaires about their physical health and quality of life. The study team will monitor for any side effects, including episodes of low blood sugar, which can happen when blood sugar drops too much.
Germany 
Greece 
Hungary 
Poland 
Romania 
Spain 
